Top

Published in:

01-11-2017 | Original Article

Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry

Authors: Natália Aydos Marcondes, Flavo Beno Fernandes, Ana Paula Alegretti, Gustavo Adolpho Moreira Faulhaber

Published in: Clinical and Experimental Medicine | Issue 4/2017

Abstract

Bruton’s tyrosine kinase (BTK) is a cytoplasmatic protein that is part of the B-cell antigen receptor signaling pathway. Our aim was to evaluate the expression of BTK in B-cell neoplasms and compare it to normal B-cell lymphocytes. After surface staining with CD19 and CD45, flow cytometry staining for intracellular BTK was performed in leukemic or mature B-cells from bone marrow or peripheral blood samples. No differences in BTK expression were identified between groups, or in comparison to control samples, there was no association between BTK expression and the clinical variables evaluated. BTK expression in B-cell neoplasms was similar to that of normal B-cell lymphocytes.

Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, et al. Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228(1):58–73. doi:10.1111/j.1600-065X.2008.00741.x.CrossRefPubMed

Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(12):2362–70. doi:10.3109/10428194.2012.695781.CrossRefPubMedPubMedCentral

Brunner C, Muller B, Wirth T. Bruton’s tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol. 2005;20(3):945–55.PubMed

Burger JA. Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012;7(1):26–33. doi:10.1007/s11899-011-0104-z.CrossRefPubMed

Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematol Am Soc Hematol Educ Progr. 2013;2013:553–60. doi:10.1182/asheducation-2013.1.553.

Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71–81. doi:10.1016/j.semcancer.2013.08.011.CrossRefPubMed

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075–80. doi:10.1073/pnas.1004594107.CrossRefPubMedPubMedCentral

Roskoski R Jr. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacol Res. 2016;113(Pt A):395–408. doi:10.1016/j.phrs.2016.09.011.CrossRefPubMed

Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.

10.

Davis BH, Dasgupta A, Kussick S, Han JY, Estrellado A. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS—part II—preanalytical issues. Cytom B Clin Cytom. 2013;84(5):286–90. doi:10.1002/cyto.b.21105.CrossRef

11.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287–96. doi:10.1182/blood-2011-01-328484.CrossRefPubMedPubMedCentral

12.

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649–57. doi:10.1038/leu.2013.358.CrossRefPubMed

13.

Fernandez-Vega I, Quiros LM, Santos-Juanes J, Pane-Foix M, Marafioti T. Bruton’s tyrosine kinase (BTK) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Arch. 2015;466(2):229–35. doi:10.1007/s00428-014-1698-z.CrossRefPubMed

14.

Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271–7. doi:10.1016/j.leukres.2013.07.028.CrossRefPubMed

15.

Futatani T, Miyawaki T, Tsukada S, Hashimoto S, Kunikata T, Arai S, et al. Deficient expression of Bruton’s tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood. 1998;91(2):595–602.PubMed

16.

Kaneko H, Kawamoto N, Asano T, Mabuchi Y, Horikoshi H, Teramoto T, et al. Leaky phenotype of X-linked agammaglobulinemia in a Japanese family. Clin Exp Immunol. 2005;140(3):520–3. doi:10.1111/j.1365-2249.2005.02784.x.CrossRefPubMedPubMedCentral

17.

Teocchi MA, Domingues Ramalho V, Abramczuk BM, D’Souza-Li L, Santos Vilela MM. BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients. Immun Inflamm Dis. 2015;3(3):171–81. doi:10.1002/iid3.57.CrossRefPubMedPubMedCentral

18.

Nisitani S, Satterthwaite AB, Akashi K, Weissman IL, Witte ON, Wahl MI. Posttranscriptional regulation of Bruton’s tyrosine kinase expression in antigen receptor-stimulated splenic B cells. Proc Natl Acad Sci USA. 2000;97(6):2737–42. doi:10.1073/pnas.050583597.CrossRefPubMedPubMedCentral

19.

Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton’s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71–83.PubMedPubMedCentral

20.

Wang SP, Iwata S, Nakayamada S, Niiro H, Jabbarzadeh-Tabrizi S, Kondo M, et al. Amplification of IL-21 signalling pathway through Bruton’s tyrosine kinase in human B cell activation. Rheumatology (Oxford). 2015;54(8):1488–97. doi:10.1093/rheumatology/keu532.CrossRef

Title: Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry
Authors: Natália Aydos Marcondes
Flavo Beno Fernandes
Ana Paula Alegretti
Gustavo Adolpho Moreira Faulhaber
Publication date: 01-11-2017
Publisher: Springer International Publishing
Published in: Clinical and Experimental Medicine / Issue 4/2017
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-016-0447-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Expression of Bruton’s tyrosine kinase in B-cell neoplasms evaluated by flow cytometry

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Associations between circulating levels of adipocytokines and abdominal adiposity in patients after acute pancreatitis

Current treatment options of T cell-associated immunotherapy in multiple myeloma

Spatial distribution of mast cells around vessels and glands in human gastric carcinoma

Overexpression of teneurin transmembrane protein 1 is a potential marker of disease progression in papillary thyroid carcinoma

Cancer treatment and the KIR–HLA system: an overview

Serum level of DNase1l3 in patients with dermatomyositis/polymyositis, systemic lupus erythematosus and rheumatoid arthritis, and its association with disease activity

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page